India CAR T-Cell Therapy Market (2026-2031)
The India CAR T-Cell Therapy Market was valued at $0 Million in 2026 and projected to reach to $0 Million by 2031, representing a compound annual growth rate of . India's CAR T-cell therapy market faces substantial headwinds as of 2026, with zero commercial market size reflecting the technology's limited accessibility and adoption.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
India CAR T-Cell Therapy Market Trends and Insights
- The market size in India stands at USD 0.0 million in 2026, reflecting the nascent adoption of this advanced immunotherapy technology across the country.
- India faces significant barriers to CAR T-cell therapy deployment, including limited healthcare infrastructure, high treatment costs, regulatory complexities, and restricted patient access to specialized oncology centers. Looking toward 2031, India's CAR T-cell therapy market is projected to remain at USD 0.0 million with a 0.0% CAGR, indicating stagnant growth during the forecast period.
- This flat trajectory underscores India's challenges in scaling advanced cell therapies, despite the country's large patient population and growing cancer burden.
- India's market development will depend on policy reforms, manufacturing localization, healthcare investment, and improved reimbursement frameworks to make CAR T-cell therapies accessible to Indian patients. The absence of significant market activity in India contrasts sharply with the global CAR T-cell therapy market, which is projected to grow from USD 7.25 billion in 2026 to USD 13.78 billion by 2031 at a 13.7% CAGR.
- India's participation in this global growth remains limited, highlighting the need for targeted interventions to bridge the innovation-access gap in the Indian healthcare ecosystem..
Key Market Statistics
- CAGR (2026-2031)
- Market Size, 2026 ~USD 0 Million
- Forecast, 2031 ~USD 0 Million
- Country India
India CAR T-Cell Therapy Market Overview
Nascent Market Stage :
India's CAR T-cell therapy market remains in early developmental phases with USD 0.0 million market size in 2026, indicating minimal commercial adoption and limited patient access to this advanced immunotherapy technology.
Regulatory and Infrastructure Barriers :
Significant challenges including limited specialized healthcare infrastructure, regulatory approval complexities, and absence of manufacturing capabilities constrain market growth and therapy availability across Indian healthcare systems.
High Treatment Costs :
Prohibitive pricing of CAR T-cell therapies remains a critical barrier in India's price-sensitive healthcare market, limiting accessibility to patient populations and slowing market penetration despite growing disease prevalence.
Future Growth Potential :
Despite current stagnation, India's large patient population, increasing oncology prevalence, and government healthcare initiatives present substantial long-term opportunities for CAR T-cell therapy market expansion post-2031.
India CAR T-Cell Therapy Market Dynamics
- The market is constrained by inadequate healthcare infrastructure, regulatory hurdles, manufacturing gaps, and affordability challenges that prevent widespread deployment across the country's healthcare system. Looking forward to 2031, India presents significant untapped potential driven by rising cancer incidence, expanding middle-class populations, and government healthcare modernization initiatives.
- Strategic investments in manufacturing capabilities, regulatory streamlining, and public-private partnerships could catalyze market emergence, though growth will likely remain gradual compared to developed markets..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- India's CAR T-cell therapy market shows zero market size in 2026 with 0.0% projected CAGR through 2031, indicating minimal commercial adoption and stagnant growth.
- India faces critical barriers including high treatment costs, limited specialized infrastructure, regulatory hurdles, and restricted patient access to advanced oncology centers.
- Despite India's large cancer patient population, CAR T-cell therapies remain inaccessible due to affordability constraints and lack of localized manufacturing capabilities.
- India's market development requires policy reforms, healthcare investment, manufacturing localization, and reimbursement frameworks to bridge the innovation-access gap.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
India CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
INDIA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 3.2 | 4.5 | 5.2 | 6.1 | 7.3 | 9.4 | 13.1 | 19.1 | 29.8 |
| LONG-TERM CARE FACILITIES | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SPECIALTY CENTERS | 1.9 | 2.7 | 3.1 | 3.6 | 4.3 | 5.5 | 7.6 | 10.9 | 28.6 |
| TOTAL | 5.1 | 7.2 | 8.3 | 9.7 | 11.7 | 14.9 | 20.7 | 30 | 29.3 |
Target Audience
- Pharmaceutical & Biotech Companies : Need India-specific market intelligence to evaluate commercialization feasibility, identify partnership opportunities, and develop localized strategies for CAR T-cell therapy introduction.
- Healthcare Investors & PE Firms : Require detailed market analysis and growth projections to assess investment opportunities in India's emerging CAR T-cell ecosystem and identify high-potential portfolio companies.
- Hospital & Healthcare Providers : Need market insights to understand technology adoption timelines, patient demand forecasts, and infrastructure requirements for integrating CAR T-cell therapies into Indian healthcare facilities.
- Government & Policy Makers : Require comprehensive market data to inform healthcare policy, regulatory frameworks, and public health initiatives supporting CAR T-cell therapy accessibility and manufacturing in India.
- Medical Device & Diagnostics Companies : Need market intelligence to identify complementary product opportunities, partnership potential, and growth prospects in India's developing CAR T-cell therapy value chain.
Key Companies in the India CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Reasons to Buy this Report
- Market Entry Strategy Development : Understand India-specific barriers, regulatory pathways, and infrastructure gaps to develop informed market entry strategies and identify optimal timing for CAR T-cell therapy commercialization in this emerging market.
- Competitive Positioning Insights : Gain intelligence on the competitive landscape, identify first-mover advantages, and assess partnership opportunities with Indian healthcare providers and government agencies to establish market presence.
- Investment Decision Support : Evaluate investment viability in India's CAR T-cell ecosystem through detailed market analysis, growth projections, and risk assessments to support capital allocation and portfolio decisions.
- Regulatory and Compliance Guidance : Access comprehensive insights into India's regulatory framework, approval processes, and compliance requirements specific to CAR T-cell therapies to navigate market entry efficiently.
- Long-term Growth Opportunity Assessment : Identify emerging catalysts, government initiatives, and demographic trends that will drive India's CAR T-cell market transformation, enabling strategic planning for future market expansion.
Frequently asked questions
What is the current market size of CAR T-cell therapy in India?
As of 2026, India's CAR T-cell therapy market size is USD 0.0 million, reflecting minimal commercial adoption and limited patient access to this advanced immunotherapy technology.
What is the projected growth rate for CAR T-cell therapy in India through 2031?
India's CAR T-cell therapy market is projected to maintain a 0.0% CAGR from 2026 to 2031, with the market size remaining at USD 0.0 million, indicating stagnant growth during the forecast period.
Why is India's CAR T-cell therapy market underdeveloped compared to global markets?
India's market remains underdeveloped due to high treatment costs, limited specialized healthcare infrastructure, complex regulatory frameworks, lack of localized manufacturing, and restricted patient access to advanced oncology centers.
What barriers prevent CAR T-cell therapy adoption in India?
Key barriers in India include prohibitive treatment costs, insufficient specialized medical facilities, regulatory complexities, absence of domestic manufacturing capabilities, and limited reimbursement support from healthcare systems.
What steps could accelerate CAR T-cell therapy market growth in India?
India's market growth could be accelerated through policy reforms, increased healthcare investment, localized manufacturing development, improved reimbursement frameworks, and establishment of specialized treatment centers in major cities.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report